Cargando…
Intrathecal pain management with ziconotide: Time for consensus?
This article summarizes recommendations made by six pain specialists who discussed the rationale for ziconotide intrathecal analgesia (ITA) and the requirement for evidence‐based guidance on its use, from a European perspective. Riemser Pharma GmbH (Greifswald, Germany), which holds the European mar...
Autores principales: | Matis, Georgios, De Negri, Pasquale, Dupoiron, Denis, Likar, Rudolf, Zuidema, Xander, Rasche, Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943290/ https://www.ncbi.nlm.nih.gov/pubmed/33690987 http://dx.doi.org/10.1002/brb3.2055 |
Ejemplares similares
-
Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain
por: Smith, Howard S, et al.
Publicado: (2009) -
Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain
por: McDowell, Gladstone C., et al.
Publicado: (2016) -
Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options
por: Deer, Timothy R, et al.
Publicado: (2019) -
Intrathecal Administration of Ziconotide as a Potential Treatment for Chronic Migraines
por: Holden, Ryan, et al.
Publicado: (2022) -
Resolution of chronic migraine headaches with intrathecal ziconotide: a case report
por: Narain, Sachin, et al.
Publicado: (2015)